Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Akebia Therapeutics (AKBA) over the last 6 years, with Dec 2024 value amounting to $210.9 million.

  • Akebia Therapeutics' Shares Outstanding (Diluted Average) rose 30.44% to $274.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year increase of 30.44%. This contributed to the annual value of $210.9 million for FY2024, which is 12.53% up from last year.
  • Per Akebia Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $210.9 million for FY2024, which was up 12.53% from $187.5 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Shares Outstanding (Diluted Average) registered a high of $210.9 million during FY2024, and its lowest value of $138.5 million during FY2020.
  • Over the past 3 years, Akebia Therapeutics' median Shares Outstanding (Diluted Average) value was $187.5 million (recorded in 2023), while the average stood at $193.7 million.
  • Data for Akebia Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 19.85% (in 2021) over the last 5 years.
  • Akebia Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $138.5 million in 2020, then rose by 19.85% to $165.9 million in 2021, then grew by 10.14% to $182.8 million in 2022, then rose by 2.56% to $187.5 million in 2023, then rose by 12.53% to $210.9 million in 2024.